vyvanse: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Takeda Pharms Usa	VYVANSE	lisdexamfetamine dimesylate	CAPSULE;ORAL	021977	NDA	Takeda Pharmaceuticals America, Inc.	59417-101-10	100 CAPSULE in 1 BOTTLE (59417-101-10)	2014-08-30
Takeda Pharms Usa	VYVANSE	lisdexamfetamine dimesylate	CAPSULE;ORAL	021977	NDA	Takeda Pharmaceuticals America, Inc.	59417-102-10	100 CAPSULE in 1 BOTTLE (59417-102-10)	2007-12-10
Takeda Pharms Usa	VYVANSE	lisdexamfetamine dimesylate	CAPSULE;ORAL	021977	NDA	Takeda Pharmaceuticals America, Inc.	59417-103-10	100 CAPSULE in 1 BOTTLE (59417-103-10)	2007-02-23
Takeda Pharms Usa	VYVANSE	lisdexamfetamine dimesylate	CAPSULE;ORAL	021977	NDA	Takeda Pharmaceuticals America, Inc.	59417-104-10	100 CAPSULE in 1 BOTTLE (59417-104-10)	2007-12-10
Takeda Pharms Usa	VYVANSE	lisdexamfetamine dimesylate	CAPSULE;ORAL	021977	NDA	Takeda Pharmaceuticals America, Inc.	59417-105-10	100 CAPSULE in 1 BOTTLE (59417-105-10)	2007-02-23
Takeda Pharms Usa	VYVANSE	lisdexamfetamine dimesylate	CAPSULE;ORAL	021977	NDA	Takeda Pharmaceuticals America, Inc.	59417-106-10	100 CAPSULE in 1 BOTTLE (59417-106-10)	2007-12-10
Takeda Pharms Usa	VYVANSE	lisdexamfetamine dimesylate	CAPSULE;ORAL	021977	NDA	Takeda Pharmaceuticals America, Inc.	59417-107-10	100 CAPSULE in 1 BOTTLE (59417-107-10)	2007-02-23
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report details the critical suppliers and manufacturing processes involved in the production of Vyvanse (lisdexamfetamine dimesylate), a prodrug of dextroamphetamine used to treat Attention Deficit Hyperactivity Disorder (ADHD). Understanding these components is vital for assessing supply chain resilience, potential risks, and competitive landscapes.

What is the Chemical Composition of Vyvanse?

Vyvanse's active pharmaceutical ingredient (API) is lisdexamfetamine dimesylate. Lisdexamfetamine is a covalent conjugate of dextroamphetamine and L-lysine. This prodrug is orally ingested and hydrolyzed in the gastrointestinal tract to dextroamphetamine, which is the pharmacologically active component. The dimesylate salt form contributes to its chemical stability and formulation properties.

Active Pharmaceutical Ingredient (API): Lisdexamfetamine dimesylate
Chemical Structure: A prodrug of dextroamphetamine, linked to L-lysine.
Mechanism of Action: Upon oral administration, lisdexamfetamine is converted to dextroamphetamine in vivo. Dextroamphetamine is a central nervous system (CNS) stimulant that increases the levels of neurotransmitters such as dopamine and norepinephrine in the brain.

Who Manufactures the Active Pharmaceutical Ingredient (API) for Vyvanse?

The primary manufacturer of the lisdexamfetamine dimesylate API for Vyvanse is Shire Pharmaceuticals, now part of Takeda Pharmaceutical Company. Takeda acquired Shire in 2019, consolidating control over the production and supply chain of Vyvanse. Shire had developed the drug and its manufacturing process.

Primary API Manufacturer: Takeda Pharmaceutical Company (formerly Shire Pharmaceuticals)
Manufacturing Location: Specific details of Takeda's API manufacturing sites for lisdexamfetamine dimesylate are proprietary. However, API manufacturing for complex molecules often occurs at specialized, large-scale facilities within Takeda's global network, potentially in regions with robust chemical manufacturing infrastructure.

What are the Key Excipients Used in Vyvanse Formulations?

Vyvanse is available in capsule and chewable tablet formulations. These formulations require various inactive ingredients, or excipients, to ensure stability, dissolution, and bioavailability. The specific excipients can vary slightly between dosage forms and manufacturing batches, but common categories include binders, fillers, disintegrants, and lubricants.

Vyvanse Capsules - Common Excipients

Capsule formulations typically require excipients that are compatible with the API and the capsule shell material (usually gelatin or hypromellose).

Microcrystalline Cellulose: A common filler and binder in capsule formulations, providing bulk and aiding powder flow.
Croscarmellose Sodium: A disintegrant that helps the capsule contents break apart in the gastrointestinal tract, facilitating drug release.
Magnesium Stearate: A lubricant that prevents the powder mixture from sticking to manufacturing equipment during capsule filling.
Capsule Shell: Composed of gelatin or hypromellose, along with opacifiers like titanium dioxide and colorants such as FD&C Blue No. 1, FD&C Red No. 3, and iron oxides, to achieve specific color profiles for different dosages.

Vyvanse Chewable Tablets - Common Excipients

Chewable tablet formulations involve a different set of excipients designed to create a palatable and readily disintegrating tablet.

Mannitol: A sugar alcohol often used as a sweetening agent and bulking agent in chewable tablets.
Sorbitol: Another sugar alcohol used for its sweetness and texturizing properties.
Fructose: A simple sugar that contributes to the palatability of chewable formulations.
Croscarmellose Sodium: Functions as a disintegrant, allowing the tablet to break down quickly upon chewing.
Stearic Acid: Acts as a lubricant and binder, improving tablet compaction and release.
Artificial Cherry Flavor: Enhances palatability.
Magnesium Stearate: Aids in tablet manufacturing by reducing friction.
Acesulfame Potassium: An artificial sweetener.

What Companies Supply Key Raw Materials for Lisdexamfetamine Dimesylate Synthesis?

The synthesis of lisdexamfetamine dimesylate is a complex multi-step chemical process. While Takeda is the primary API manufacturer, they likely source various precursor chemicals and reagents from specialized chemical suppliers. Specific suppliers for these intermediates are typically confidential due to competitive reasons and supply chain security. However, the types of raw materials involved suggest the involvement of companies specializing in fine chemicals, chiral intermediates, and amino acid derivatives.

Dextroamphetamine Precursors: The synthesis would require starting materials or intermediates leading to dextroamphetamine. These are often derived from amphetamine synthesis pathways.
L-Lysine or Lysine Derivatives: As lisdexamfetamine is a conjugate with L-lysine, a source of this amino acid or a protected derivative thereof would be essential.
Coupling Reagents: Chemicals used to facilitate the formation of the amide bond between dextroamphetamine and lysine.
Salting Agents: Specifically, a source of methanesulfonic acid or a methanesulfonate salt to form the dimesylate salt.
Solvents and Catalysts: Various organic solvents and catalysts are indispensable in multi-step organic synthesis.

Given the sensitive nature of amphetamine-related compounds and the strict regulatory environment (e.g., DEA scheduling in the US), the suppliers for these precursors would be highly vetted and operate under stringent controls.

What are the Major Contract Manufacturing Organizations (CMOs) Involved in Vyvanse Production?

While Takeda is the primary manufacturer of the API, large pharmaceutical companies often utilize contract manufacturing organizations (CMOs) for specific stages of drug product formulation, packaging, and distribution, especially for global supply chains. Identifying specific CMOs for Vyvanse can be challenging as these agreements are often not publicly disclosed. However, established CMOs with capabilities in solid oral dosage forms (capsules and tablets) and experience with controlled substances would be potential partners.

Potential CMO Categories:
- Formulation and Finished Dosage Manufacturing: Companies specializing in blending APIs with excipients, manufacturing tablets/capsules, and quality control.
- Packaging and Serialization: CMOs providing blister packaging, bottle filling, and serialization services to meet track-and-trace regulations.
- Logistics and Distribution: Specialized pharmaceutical logistics providers managing the cold chain (if applicable, though not typical for Vyvanse) and controlled substance distribution.

It is plausible that Takeda maintains significant in-house manufacturing capacity for critical steps, especially given the controlled substance status of dextroamphetamine, but may leverage CMOs for capacity, regional support, or specialized services.

What are the Regulatory and Supply Chain Controls for Vyvanse Manufacturing?

As a stimulant medication containing dextroamphetamine, Vyvanse is a Schedule II controlled substance in the United States under the Controlled Substances Act, and similarly regulated in other countries. This classification imposes rigorous controls on its manufacturing, distribution, and record-keeping.

Drug Enforcement Administration (DEA) Quotas: The DEA sets annual aggregate production quotas for Schedule II controlled substances, limiting the total amount of API that can be manufactured and imported into the U.S. Takeda must operate within these quotas for lisdexamfetamine dimesylate.
Site Registrations and Inspections: All facilities involved in the manufacturing, handling, storage, and distribution of Schedule II substances must be registered with the DEA and are subject to regular inspections to ensure compliance with security, record-keeping, and diversion prevention protocols.
Security Requirements: Manufacturing and storage facilities must meet strict physical security standards to prevent theft and diversion. This includes secure storage areas, access controls, and surveillance systems.
Record Keeping and Reporting: Comprehensive and accurate records of all transactions, from raw material acquisition to finished product distribution, are mandatory. This includes detailed inventories and periodic reports to the DEA.
International Controls: Similar national regulatory bodies worldwide enforce controls on psychostimulant medications, requiring compliance with local pharmaceutical manufacturing standards (e.g., Good Manufacturing Practices or GMP) and controlled substance regulations.

These controls significantly impact the supply chain, limiting the number of potential manufacturers and distributors and increasing the complexity and cost of operations.

What is the Global Market for Vyvanse and its Impact on Supply Chain Demands?

Vyvanse is a blockbuster drug, generating billions of dollars in annual revenue for Takeda. Its widespread use for ADHD in children and adults across major global markets necessitates a robust and scalable supply chain.

Market Size: Vyvanse (lisdexamfetamine dimesylate) has consistently been one of the top-selling ADHD medications globally. Takeda reported net sales of approximately $4.0 billion for Vyvanse in fiscal year 2022 [1].
Geographic Reach: Vyvanse is approved and marketed in North America, Europe, Australia, and other regions. The largest market by revenue is typically the United States.
Demand Fluctuations: While demand for ADHD medications is generally stable, seasonal factors or increased awareness campaigns can influence demand. For Vyvanse, the primary driver is its prescription volume for ADHD treatment.
Supply Chain Implications: The substantial global demand means Takeda must maintain significant manufacturing capacity for both the API and the finished drug product. This requires reliable access to raw materials, robust manufacturing processes, and an efficient distribution network that can handle controlled substances. Any disruption in this complex chain, whether due to raw material shortages, manufacturing issues, or regulatory hurdles, can have immediate and significant impacts on drug availability.

What are the Potential Supply Chain Risks and Mitigation Strategies for Vyvanse?

The reliance on a single API manufacturer (Takeda) and the controlled substance status of Vyvanse present inherent supply chain risks.

Single Source API Risk: If Takeda's API manufacturing capacity is compromised (e.g., due to a plant issue, natural disaster, or regulatory action), the entire Vyvanse supply could be at risk.
- Mitigation: Takeda likely maintains multiple production lines or backup manufacturing sites for its critical APIs. They may also hold significant safety stock of the API. Exploring dual-sourcing for key intermediates, though challenging for controlled substances, could be a long-term strategy if feasible and approved by regulators.
Regulatory Compliance Changes: Evolving DEA regulations or international drug control policies could impact manufacturing or distribution.
- Mitigation: Proactive engagement with regulatory bodies, maintaining rigorous compliance programs, and investing in secure supply chain technologies (e.g., serialization and track-and-trace systems) are crucial.
Raw Material Availability: While Takeda controls API production, disruptions in the upstream supply of precursor chemicals or reagents could impact API synthesis.
- Mitigation: Establishing strong relationships with multiple, qualified suppliers for key raw materials and maintaining adequate inventory levels for critical inputs.
Geopolitical Instability and Global Logistics: Disruptions in international shipping, trade restrictions, or geopolitical events can affect the movement of raw materials and finished products.
- Mitigation: Diversifying logistics partners and routes, utilizing regional warehousing, and maintaining close monitoring of global events that could impact supply chains.
Counterfeiting and Diversion: Due to its high market value and controlled status, Vyvanse is a target for counterfeiting and illegal diversion.
- Mitigation: Implementing robust anti-counterfeiting measures, including advanced packaging security features and serialization, and working with law enforcement to combat illicit markets.

Conclusion

The supply chain for Vyvanse is characterized by centralized API manufacturing by Takeda Pharmaceutical Company, complex synthesis requiring specialized raw materials, and stringent regulatory oversight due to its Schedule II controlled substance status. The drug's significant market presence necessitates a highly resilient and secure supply chain. Key risks revolve around single-source API production and the inherent complexities of controlled substance manufacturing and distribution. Takeda's operational strategy must focus on robust compliance, secure manufacturing, and diversified logistics to ensure consistent global availability.

Key Takeaways

Takeda Pharmaceutical Company is the primary manufacturer of the lisdexamfetamine dimesylate API for Vyvanse.
The drug is a Schedule II controlled substance, mandating strict DEA oversight, security, and record-keeping throughout its supply chain.
Vyvanse formulations utilize common pharmaceutical excipients such as microcrystalline cellulose, croscarmellose sodium, and magnesium stearate for capsules, and mannitol, sorbitol, and flavorings for chewable tablets.
Suppliers for the complex chemical precursors of lisdexamfetamine dimesylate operate under high regulatory scrutiny and are typically confidential.
Global demand for Vyvanse, exceeding $4 billion annually, underscores the need for a robust and uninterrupted supply chain.
Key supply chain risks include single-source API dependence, regulatory changes, raw material disruptions, and geopolitical instability.

Frequently Asked Questions

Does Takeda manufacture the Vyvanse API in-house, or do they use contract manufacturers for this stage? Takeda is understood to be the primary, likely in-house, manufacturer of the lisdexamfetamine dimesylate API. While they may use contract organizations for specific formulation or packaging steps, the critical API synthesis is typically managed internally for controlled substances.
What are the implications of Vyvanse being a Schedule II controlled substance for its supply chain? The Schedule II classification imposes rigorous DEA regulations on production quotas, manufacturing site security, record-keeping, and distribution protocols. This limits the number of potential manufacturers and distributors and significantly increases operational complexity and compliance costs.
Are there any alternative suppliers for the lisdexamfetamine dimesylate API if Takeda's production is disrupted? Due to the complex synthesis, controlled substance status, and proprietary manufacturing processes, there are likely no readily available alternative suppliers for the lisdexamfetamine dimesylate API. This highlights the critical nature of Takeda's internal manufacturing capabilities and contingency planning.
How does Takeda ensure the quality and authenticity of the raw materials used in Vyvanse synthesis? Takeda would have stringent quality control protocols for all incoming raw materials, including supplier qualification programs, batch testing, and adherence to Good Manufacturing Practices (GMP). For controlled substance precursors, these checks are even more rigorous.
What specific excipients are used in the chewable tablet formulation of Vyvanse? The chewable tablet formulation of Vyvanse primarily contains mannitol, sorbitol, fructose, croscarmellose sodium, stearic acid, artificial cherry flavor, magnesium stearate, and acesulfame potassium. These are selected for palatability, disintegration, and tablet manufacturing properties.

Citations

[1] Takeda Pharmaceutical Company Limited. (2023). Takeda Reports Fiscal Year 2022 Results. Retrieved from https://www.takeda.com/investors/reports/financial-results/ (Specific report details would be within the link for FY2022 results, often a downloadable PDF or web presentation.)

Suppliers and packagers for vyvanse

vyvanse

Vyvanse (Lisdexamfetamine Dimesylate) Key Manufacturing and Supply Chain Components